HALO · Halozyme Therapeutics Inc
Price
Snapshot
50 fields · last close| Market Cap | $12.47B |
| P/E | 30.15 |
| Float | 117.0M |
| Beta | 0.94 |
| Volatility | 23.5% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 73.2 |
| Price | 109.86 |
| Change | +0.00% |
| Prev Close | 109.86 |
| Open | 106.96 |
| Day Low | 106.65 |
| Day High | 109.99 |
| Avg Vol | 3 |
| Avg $ Vol | $312.2M |
| 52W High | 116.84 |
| 52W Low | 61.23 |
| 52W Pos | 87.4% |
| From High | −5.98% |
| From Low | +79.42% |
| Max DD 1Y | −24.13% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −0.34% |
| SMA 50 | +6.73% |
| SMA 200 | +40.26% |
| RSI (14) | 53.2 |
| Vol 30D | 26.5% |
| Vol 90D | 41.8% |
| 1Y Range | 61–117 |
| Daily bars | 526 |
| Perf Week | −3.55% |
| Perf Month | +0.18% |
| Perf Quarter | +36.00% |
| Perf Half Y | +70.35% |
| Perf Year | +46.60% |
| Perf YTD | +56.25% |
| Prev Day | +0.00% |
| Clavix | B |
| Debt / Eq | 43.89 |
| Curr Ratio | 4.66 |
| Int Cover | 39.7× |
| FCF Margin | 46.2% |
| Rev Growth | +37.5% |
| Profit | Profitable |
| Leverage | Very High |
| Sector rank | 16 / 35 |
Clavix risk grade
regraded every trading dayHALO grades B, 73.2 of 100. Steadiest on Macro Resilience (67), most exposed on Price Stability (56, mixed). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 16 of 35 in Biotechnology by Clavix score.
How rough the ride is
| HALO | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.94 | 0.50 |
| Volatilityannualized | 23.5% | 14.4% |
| Max drawdown, past yearworst peak-to-trough fall | −24.1% | — |
| Typical daily movemedian absolute daily change | 1.25% | — |
| Days beyond ±3%of the last 252 sessions | 30 (12%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| HALO | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.94 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| HALO | |
|---|---|
| 1 week | −3.5% |
| 1 month | +0.2% |
| Year to date | +56.3% |
| 1 year | +46.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| HALO | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 6 Aug |
| Average score0 most bearish, 100 most bullish | 68 |
| Bullish · bearisharticles above 60 · below 40 | 21 · 1 |
| Directionarticles whose tone is improving vs worsening | 21 ↑ 1 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| HALO | |
|---|---|
| Revenue growthyear over year | +37.5% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openHalozyme announced on September 30, 2026 that it has appointed James 'Jim' Daly to its Board of Directors.
Halozyme Therapeutics announced the appointment of Jim Daly, a biopharmaceutical executive with over 30 years of commercial leadership experience, to its Board of Directors.
Halozyme filed an 8-K on September 28, 2026, reporting that James Daly was elected to its Board of Directors, joining the class whose terms end at the 2029 annual meeting. He was not assigned to any board committee and will receive the same cash and equity compensation as other non-employee directors.
On September 22, 2026, Halozyme Therapeutics completed the sale of $1.5 billion in convertible senior notes due 2033, carrying a 1.50% interest rate. The sale included $200 million from an over-allotment option exercised by initial buyers, and the notes were sold privately to large institutional investors without SEC registration.
Halozyme priced a $1.3 billion private offering of convertible senior notes (debt that can be converted into stock) due 2033, upsized from an originally announced $1.05 billion. The notes carry a 1.50% interest rate and convert into stock at about $139.84 per share, a 27.5% premium over the $109.68 closing price on September 17, 2026. Buyers are limited to large institutional investors under SEC Rule 144A.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| TWST | Twist Bioscience Corp | D+ | $12.42B | — | 2.17 | Compare |
| BBIO | BridgeBio Pharma Inc | B | $13.15B | — | 0.95 | Compare |
| MDGL | Madrigal Pharmaceuticals Inc | B | $11.54B | — | -1.08 | Compare |
| ASND | Ascendis Pharma A/S | B+ | $14.21B | 17.03 | 0.39 | Compare |
| EXEL | Exelixis Inc | B+ | $14.47B | 16.81 | 0.44 | Compare |
| NBIX | Neurocrine Biosciences Inc | B+ | $14.55B | 20.63 | 0.34 | Compare |
| KRYS | Krystal Biotech Inc | B | $9.54B | 39.51 | 0.65 | Compare |
| CYTK | Cytokinetics Inc | B | $9.12B | — | 0.42 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.